drugset / Trial / NCT01928368

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

NCT01928368

Phase 1 Completed 70 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy subjects and subjects with mild atopic asthma.

Timeline

Start
2013-08
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Astegolimab Monoclonal antibody Subcutaneous

Indications